All News

"Pandemic meetings were different because they were virtual. To be honest, those weren’t really good. I prefer to go to the meeting and be with other people and see them face-to-face," says Robert Gossett, MD.

"ChatGPT not only has a low rate of correct answers regarding clinical questions in urologic practice, but also makes certain types of errors that pose a risk of spreading medical misinformation," says Christopher M. Deibert, MD, MPH.

“We are excited to report that a simple, low-cost intervention can positively [affect] young men’s willingness to engage with their health," says Wade Gutierrez.

"One of the notable things was the complications are frequent—which is something that was previously known about these surgeries—but they're minor," says Kayla Blickensderfer.

Projections were made under 3 different circumstances: the rate of women entering urology continues to follow logistic growth, there is no further growth of women into urology, and retirement rates among women mirror that of men in urology.

"Overall, there are plenty of options for keeping cash. The trick is determining the best option for your needs," writes Jeff Witz, CFP.

"It gives me a very rewarding experience…. I see patients with low-grade prostate cancer and when they become advanced prostate cancer, I already have a good relationship with them and don’t have to send them somewhere else," says Abhinav Sidana, MD, MPH.

Disitamab vedotin is a HER2-targeted antibody-drug conjugate and toripalimab is a PD1-inhibitor.

"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.

"Among our accomplishments were the first robotic ureteral reconstructions and completing our first 100 robotic cases within the first half-year," says Michael W. Witthaus, MD.

Correct code selection depends on whether procedure is simple or complex.

“This research shows the importance of diversity in clinical trials," said lead author Daniel J. George, MD.

At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.

“Both the SWOG S1011 and the LEA trial show very clearly that a bilateral standard node dissection confined to the true pelvis is the standard of care for patients with curable muscle-invasive bladder cancer," says Seth P. Lerner, MD, FACS.

“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.

In this patient population, erdafitinib reduced the risk of death by 36% versus physician's choice of chemotherapy.

"In EV-103 dose escalation/cohort A, the safety profile of the combination was manageable, with no new safety concerns observed at nearly 4 years of follow-up," said Shilpa Gupta, MD.

At a median follow-up of about 50 months, lenvatinib plus pembrolizumab maintained an overall survival benefit compared with sunitinib in patients with advanced renal cell carcinoma.

The antibody-drug conjugate trastuzumab deruxtecan is being explored across a wide-range of HER2-positive solid tumors, including difficult-to-treat cancers.

The benefit in radiographic progression-free survival extended across all subgroups of patients with HRR-deficient metastatic castration-resistant prostate cancer.

“These results further support the importance of screening for germline and somatic BRCA1/2 alterations to deliver more precise care for our patient," says David Olmos, MD, PhD.

Overall, 86% maintained a response for greater than 6 months.

Belzutifan plus lenvatinib elicited promising antitumor activity with a manageable safety profile as a second-line or later treatment for patients with advanced renal cell carcinoma.

“Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” said Daniel Y. Song, MD.

A total of 398 patients with mCRPC, unselected for homologous recombination repair gene alterations.were included in the safety cohort.

The proportion of patients who discontinued initial ARI treatment was 30.4% for darolutamide compared with 40.8% for enzalutamide and 46.0% for apalutamide.

“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.

"The pressures on physicians are making it extremely difficult to run a medical practice, and something needs to be done," says William C. Reha, MD, MBA.

"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.

"This is the first data to show that antegrade instillation of UGN-101 had lower ureteral stricture rates compared [with] retrograde approaches,” said Josh Gottlieb, DO.